Home › Left Ventricular Dysfunction › Pennsylvania › Pittsburgh
Left Ventricular Dysfunction clinical trials in Pittsburgh, PA
3 studies for Left Ventricular Dysfunction are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
RecruitingPhase 2/3
- Children's Hospital of Pittsburgh ( Site 0010), Pittsburgh
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- UPMC Children's Hospital of Pittsburgh - Cardiology, Pittsburgh
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
RecruitingPhase 3
- UPMC Children's Hospital of Pittsburgh - Cardiology, Pittsburgh
Left Ventricular Dysfunction trials in other cities
- Cleveland, OH4 studies
- New York City, NY4 studies
- Boston, MA3 studies
- Philadelphia, PA3 studies
- Aurora, CO3 studies
- Atlanta, GA3 studies
- Ann Arbor, MI3 studies
- St. Louis, MO3 studies
- Dallas, TX3 studies
- Houston, TX3 studies
- The Bronx, NY3 studies
- Cincinnati, OH3 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Lung Cancer23 studies
- Prostate Cancer23 studies
- Stroke22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.